Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer ...

Entasis’ Nuzolvence and GSK’s Blujepa are the first antibiotic approvals in gonorrhoea in over 30 years in the US.

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals’ Daybue Stix (trofinetide).

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.

Pharmaceutical packaging has always been defined by innovation, barrier protection, sterility assurance, and tamper-evident seals.

The framework has had a lukewarm reaction, with trade association EFPIA saying the policies are “not strong enough”.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Zealand Pharma and OTR Therapeutics are to collaborate to discover and develop therapies for several targets in metabolic diseases.

Novartis and Relation's target discovery deal falls under Novartis’ wider ploy to strengthen its immunology portfolio.

The UK's 14.5% drug rebate reduction may help to quell souring pharma sentiments, which stem from the nation's low spending on innovative drugs.